Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diffuse Systemic Sclerosis and variants as per ACR criteria~* Medically refractory disease~* Adequate Organ Function - Pulmonary function~* Renal function, Cardiac function defined as:~* SGOT (AST) or SGPT (ALT) \<5 x upper limit of normal~* Diagnosis of SLE - Medically refractory disease~Exclusion Criteria:~* Karnofsky/Lansky \<60%

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Reduced Intensity Regimen for Refractory SLE (Type: EXPERIMENTAL): RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
- Reduced Intensity Regimen for SSc (Type: EXPERIMENTAL): RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).

Based on this trial design, predict the completion outcome and termination type (if applicable).